SCHEMBL607249

SCHEMBL607249

N#C[C@@H]1CCN(Cc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.53
BCHE P06276 5/20 0.53
BACE1 P56817 4/20 0.53
CCR3 P51677 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LTA4H P09960 2/20 0.50
SIGMAR1 Q99720 1/20 0.50
HRH3 Q9Y5N1 1/20 0.49
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607250 1.00 ACHE (0.53) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL3273178 1.00 ACHE (0.53) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL6646032 0.90 CYP2D6 (0.60) ACHEBCHEBACE1CYP1A2CYP3A4
SCHEMBL311417 0.90 ACHE (0.61) ACHEBCHEBACE1CCR3ALDH1A1
Hydrochloric Acid SCHEMBL312187 0.88 ACHE (0.59) ACHEBCHEBACE1CCR3ALDH1A1
SCHEMBL8790984 0.86 LTA4H (0.56) ACHECYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5016797 0.84 ACHE (0.54) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL6567147 0.82 ROCK2 (0.47) BCHELTA4HDRD2DRD4
SCHEMBL7226381 0.81 ALDH1A1 (0.54) ACHEBCHEBACE1CCR3CYP1A2
SCHEMBL24027115 0.78 FUCA1 (0.55) ACHEBCHEBACE1CCR3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
EP-1693364-B1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI SANKYO CO LTD (JP) 2015-05-20 EP disclosed
US-8946422-B2 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2015-02-03 US disclosed
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 US disclosed
WO-2012037299-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
US-20120040959-A1 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-8044204-B2 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2011-10-25 US disclosed
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7994344-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
EP-1687296-A1 ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES Warner-Lambert Company LLC (US) 2006-08-09 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed
US-20060019986-A1 (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions CUMBRE INC. (US) 2006-01-26 US disclosed
WO-2005049602-A1 QUINOLONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-06-02 WO disclosed
WO-2005049605-A1 ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2005-06-02 WO disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed
US-5466828-A Chiral 3-cyano-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1995-11-14 US disclosed
WO-1995001962-A1 PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES WARNER-LAMBERT COMPANY (US) 1995-01-19 WO disclosed
US-5347017-A Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1994-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019986-A1 (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions RPS6KA1, RIF1, RPS27L ACHE 2806/4885BCHE 3644/4885BACE1 4415/4885
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ACHE 3946/4885BCHE 3379/4885BACE1 405/4885
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 ACHE 4663/4885BCHE 2601/4885BACE1 2486/4885
US-20120040959-A1 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS TOP1, TOP2B, DNA2 ACHE 2309/4885BCHE 3475/4885BACE1 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.